Search

Your search keyword '"Ayala, Rosa"' showing total 729 results

Search Constraints

Start Over You searched for: Author "Ayala, Rosa" Remove constraint Author: "Ayala, Rosa" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
729 results on '"Ayala, Rosa"'

Search Results

2. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group

3. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

6. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

7. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

8. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

9. Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

11. Author Correction: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA

12. Supplementary Data 1 from Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma

13. Data from Short-Chain Fatty Acid Production by Gut Microbiota Predicts Treatment Response in Multiple Myeloma

14. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

15. Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial

16. Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges.

17. The prognostic impact of non‐driver gene mutations and variant allele frequency in primary myelofibrosis.

18. Efficacy of Consolidation Therapy with Ponatinib 15mg on Treatment-Free Remission Rate in Patients with Chronic Myeloid Leukemia. Results of the Ponazero Trial

19. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens

22. Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia

24. Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

26. P-473 Real-world evidence of statins and oral antidiabetics for multiple myeloma

27. POSTER: MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

28. MPN-381 BMS-986158, a Potent Bromodomain and Extraterminal Domain Inhibitor (BETi), as Monotherapy and in Combination With Ruxolitinib (RUX) or Fedratinib (FED) in Intermediate-Risk or High-Risk Myelofibrosis (MF): Results From a Phase I/II Study

29. P-062 Real-world evidence of bisphosphonates and denosumab for multiple myeloma

31. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

32. P1100: PET INTERIM RESULTS COULD PROMPTLY SELECT FOLLICULAR LYMPHOMA PATIENTS IN NEED OF MAINTENANCE THERAPY. POTENTIAL ADDITIONAL VALUE OF CFDNA.

33. P948: REAL-WORLD EVIDENCE OF BISPHOSPHONATES FOR MULTIPLE MYELOMA

34. S213: BMS-986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE- OR HIGH-RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

36. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

38. Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study

39. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

40. Analysis of SNP Array Abnormalities in Patients with DE NOVO Acute Myeloid Leukemia with Normal Karyotype

42. Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

43. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

44. Semantic Matching of Components at Run-Time in Distributed Environments

47. Global real-life analysis of survival and usage of therapies in multiple myeloma

49. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

50. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Catalog

Books, media, physical & digital resources